Inhibition of SOS1 can increase the chemosensitivity of KRAS-amplified cancer cells to MEK inhibition and the SOS1 inhibitor BI-3406 has been demonstrated to synergize with the MEK inhibitor trametinib [21, 29]. Here, KRAS is linked to cancer.